HomeAI · summaries
Storia in 5 fonti
Novo Nordisk rocked by late-stage cardiovascular drug failure
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novo setback casts doubt on a new way to treat heart disease
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
- ·
cnbc.com
Novo Nordisk shares dive 9% after heart medicine fails trial
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
